Positron Emission Tomography and Near-Infrared Fluorescence Imaging of Vascular Endothelial Growth Factor with Dual-Labeled Bevacizumab. - Wikidata - wikimedia - TriplyDB

Positron Emission Tomography and Near-Infrared Fluorescence Imaging of Vascular Endothelial Growth Factor with Dual-Labeled Bevacizumab.

Positron Emission Tomography and Near-Infrared Fluorescence Imaging of Vascular Endothelial Growth Factor with Dual-Labeled Bevacizumab.

http://www.wikidata.org/entity/Q35646547

about

Biomedical applications of functionalized hollow mesoporous silica nanoparticles: focusing on molecular imaging Pharmacokinetic issues of imaging with nanoparticles: focusing on carbon nanotubes and quantum dots Detection of rapalog-mediated therapeutic response in renal cancer xenografts using ⁶⁴Cu-bevacizumab immunoPET Antibody-based imaging of HER-2: moving into the clinic.Dynamic Positron Emission Tomography Imaging of Renal Clearable Gold Nanoparticles.Detection of vascular endothelial growth factor in colon cancer xenografts using bevacizumab based near infrared fluorophore conjugate.Engineering of hollow mesoporous silica nanoparticles for remarkably enhanced tumor active targeting efficacy Theranostic unimolecular micelles based on brush-shaped amphiphilic block copolymers for tumor-targeted drug delivery and positron emission tomography imaging New radiotracers for imaging of vascular targets in angiogenesis-related diseases.In vivo tumor vasculature targeted PET/NIRF imaging with TRC105(Fab)-conjugated, dual-labeled mesoporous silica nanoparticles.PET/SPECT imaging of hindlimb ischemia: focusing on angiogenesis and blood flow.VEGF₁₂₁-conjugated mesoporous silica nanoparticle: a tumor targeted drug delivery system.Positron emission tomography imaging of angiogenesis in a murine hindlimb ischemia model with 64Cu-labeled TRC105 Pravastatin stimulates angiogenesis in a murine hindlimb ischemia model: a positron emission tomography imaging study with (64)Cu-NOTA-TRC105 PET of follicle-stimulating hormone receptor: broad applicability to cancer imaging Positron emission tomography and optical imaging of tumor CD105 expression with a dual-labeled monoclonal antibody.In vivo targeting and positron emission tomography imaging of tumor vasculature with (66)Ga-labeled nano-graphene In vivo targeting and imaging of tumor vasculature with radiolabeled, antibody-conjugated nanographene.Positron emission tomography imaging of tumor angiogenesis with a 66Ga-labeled monoclonal antibody.Graphene: a versatile nanoplatform for biomedical applications.Radiolabeled γ-AApeptides: a new class of tracers for positron emission tomography.ImmunoPET and near-infrared fluorescence imaging of CD105 expression using a monoclonal antibody dual-labeled with (89)Zr and IRDye 800CW.Chelator-Free Labeling of Layered Double Hydroxide Nanoparticles for in Vivo PET Imaging In a "nutshell": intrinsically radio-labeled quantum dots.Molecular imaging of insulin-like growth factor 1 receptor in cancer.Immuno-PET of tissue factor in pancreatic cancer.Multimodality imaging of breast cancer experimental lung metastasis with bioluminescence and a monoclonal antibody dual-labeled with 89Zr and IRDye 800CW.PET Imaging of VEGFR-2 Expression in Lung Cancer with 64Cu-Labeled Ramucirumab Positron emission tomography imaging of tumor angiogenesis with a (61/64)Cu-labeled F(ab')(2) antibody fragment Tumor vasculature targeting and imaging in living mice with reduced graphene oxide.Positron emission tomography imaging of vascular endothelial growth factor receptor expression with (61)Cu-labeled lysine-tagged VEGF121.PET imaging of CD105/endoglin expression with a ⁶¹/⁶⁴Cu-labeled Fab antibody fragment HaloTag as a reporter gene: positron emission tomography imaging with (64)Cu-labeled second generation HaloTag ligands Imaging tumor angiogenesis in breast cancer experimental lung metastasis with positron emission tomography, near-infrared fluorescence, and bioluminescence In vivo tumor targeting and image-guided drug delivery with antibody-conjugated, radiolabeled mesoporous silica nanoparticles.Multimodality imaging of CXCR4 in cancer: current status towards clinical translation.Functionalized upconversion nanoparticles: versatile nanoplatforms for translational research Positron emission tomography imaging of CD105 expression in a rat myocardial infarction model with (64)Cu-NOTA-TRC105.Radioiodination of BODIPY and its application to a nuclear and optical dual functional labeling agent for proteins and peptides.Targeting angiogenesis for radioimmunotherapy with a 177Lu-labeled antibody.

P2860

Q26827998-F081DE18-5B55-4064-A391-585795C7A5B0 Q28388580-247E2FE2-AB2E-40B1-B48B-206FF8F57A5E Q28487987-B8E48105-CDD9-4445-96AB-8DDCD42C09FD Q30423880-9009FD76-1F07-4D50-8257-900652FC685A Q30759992-BDFFF938-5D91-4F09-83B8-3242D9DD353A Q33576784-CA298C70-3EC2-4453-9FD4-B67391745FE9 Q33687218-E2460F6E-60D1-41CA-8EA7-867ECA14506A Q34178035-2AA41319-151C-4E24-AE46-F9044E2A3158 Q34216877-6404B29D-56ED-43A9-91FE-D04B3F62974F Q34446399-7F482048-0CAE-432B-9A70-6D311C5669E2 Q34464099-E923954B-DCC4-4532-8E80-B5BE4C1407C4 Q34674541-F991048A-AAF1-4573-A56F-449D17C09B3D Q34759659-91920A91-5571-4A32-A33B-59E620F7756A Q35071225-21D66D50-28E7-4D5C-8215-92E2BACDB062 Q35153873-E1EE007D-8B16-486C-A602-5FCD2C1EAA47 Q35809541-8184E1DF-13D8-483D-88AD-270AC56161FA Q35854802-5CDF7A06-DF2F-4F0F-99CD-87E225BA4B84 Q35856996-BC9D6B61-356B-4F1D-8BE0-9CD237AF57C6 Q36034526-EF560D8C-7D39-48A2-91E1-6A36B6147C10 Q36035392-8181DFDB-CC1B-4A3A-ACD7-AC6EA21A6142 Q36096541-EF64E9C9-D102-4016-AE13-BA8E83601F7F Q36185354-EF4CF795-CA7D-40F0-AA35-D3EFDE5C0308 Q36301189-CAD957D8-3E5A-4038-BBBA-544C6638E891 Q36337263-F452048D-3FC3-4C74-8AD8-2A39FD0A74C8 Q36337268-C46EA886-CA22-4814-A8CB-B30E30D0299E Q36374066-26A8377C-B92D-468D-B851-7CC75279C159 Q36406701-9EB494CE-85A6-4624-96BD-39E681798880 Q36535436-5B007C67-49A0-47EA-AB3C-E0646E3161EA Q36586091-59711B65-CED2-4CBC-908D-610D6EE831BC Q36604948-46CB13F1-402F-4271-A5FC-3EBA139A0E99 Q36746567-6A3BFFFA-8023-4B0D-BD86-3F5506CE7C5B Q36763112-EC742AB1-75A8-4972-A860-3BCA6547710B Q36788992-EEB32AE4-B924-4479-B7C5-F602600357FE Q36996613-06023522-DAC6-46E5-B6F2-F33FCD69B129 Q37327759-C76DD613-455D-4AEB-AA1F-A4CDD33CB7D8 Q37337280-002C7784-F1FC-4BB7-BC87-E4D7FD2B6C75 Q37354263-DE460257-D11E-4414-B3F1-CB376D5EAF63 Q37402601-5C55B1AA-6756-47A6-8BF7-F6EFDDF62F9E Q42204570-37F63A43-A4BA-4456-882E-87FAE59A3E96 Q47777542-93F9CC00-F7FB-46D7-AC72-FE72F9E83766

P2860

Positron Emission Tomography and Near-Infrared Fluorescence Imaging of Vascular Endothelial Growth Factor with Dual-Labeled Bevacizumab.

http://www.wikidata.org/entity/Q35646547

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Positron Emission Tomography a ...... with Dual-Labeled Bevacizumab.

@ast

Positron Emission Tomography a ...... with Dual-Labeled Bevacizumab.

@en

type

label

Positron Emission Tomography a ...... with Dual-Labeled Bevacizumab.

@ast

Positron Emission Tomography a ...... with Dual-Labeled Bevacizumab.

@en

prefLabel

Positron Emission Tomography a ...... with Dual-Labeled Bevacizumab.

@ast

Positron Emission Tomography a ...... with Dual-Labeled Bevacizumab.

@en

P1433

Q35646547-8DF76B60-417B-4B77-A442-4ADE8A9B39BE

P1476

Q35646547-BE7D2BD6-EA2A-4B18-B288-274B8A64B81E

P2093

Q35646547-1264B7DF-9CCE-4290-A38A-29E25BC653D2

Q35646547-6F905D40-F7FE-48AF-AAC3-2D09326F952F

Q35646547-7FDAA6B9-1EDA-48A8-8C8A-C47C9E7000E1

Q35646547-95E6F3D4-2AC1-4206-937A-562257A9E043

Q35646547-C04CCD8B-4C94-4B33-8CB3-2083DDFB644F

Q35646547-E3B4AA53-2247-4E44-B81E-367D80DCC5F7

P2860

Q35646547-03741B1F-C332-4D64-9A87-190535A30D40

Q35646547-053643B2-5666-41F7-B5E9-55E48D563B9B

Q35646547-07130798-2D95-4176-8B90-8A15AB5950D8

Q35646547-18D3FE1D-5367-4BF7-A1D2-29945E4D920C

Q35646547-1E79A4F6-7998-41DE-BD5F-00254E0CFF64

Q35646547-1FD5FFC2-36F6-4BF5-97B9-383B51509F58

Q35646547-20695A8A-0DB8-407C-B345-9206035E13EA

Q35646547-283ED180-5830-4586-BD70-798E8A253726

Q35646547-33563AEC-D80D-4EE8-A8D6-A9DB1411AA7A

Q35646547-38447F15-004E-4C30-A6EC-428404DB4EAD

P304

Q35646547-856720B2-3C29-4432-9786-AC2AB50B5BBD

P31

Q35646547-072088C4-55EA-4D0B-87D3-9C202CB1FF93

P433

Q35646547-41E99496-EB52-420E-94B0-0C0D54D839F4

P478

Q35646547-F166E2B4-6C9E-479E-BF82-4C63E469A998

P577

Q35646547-2D065C00-27BD-4B11-AFFC-04B8D1323006

P698

Q35646547-569C8F39-8248-438D-A0B0-49B43A3F012E

P921

Q35646547-975A2D88-4D36-4E30-80D0-713A3A9524C7

Q35646547-C38AFB8D-3428-4226-AD4A-85BD5CB67946

P932

Q35646547-98AD4056-1494-46E7-9030-3C73FE3C99ED

P1433

American journal of nuclear medicine and molecular imaging

P1476

Positron Emission Tomography a ...... with Dual-Labeled Bevacizumab.

@en

P2093

Hao Hong

http://www.w3.org/2001/XMLSchema#string

Jonathan W Engle

http://www.w3.org/2001/XMLSchema#string

Todd E Barnhart

http://www.w3.org/2001/XMLSchema#string

Weibo Cai

http://www.w3.org/2001/XMLSchema#string

Yin Zhang

http://www.w3.org/2001/XMLSchema#string

Yunan Yang

http://www.w3.org/2001/XMLSchema#string

P2860

Tumor angiogenesis: therapeutic implications

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

Angiogenesis: an organizing principle for drug discovery?

Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer

Interaction between bevacizumab and murine VEGF-A: a reassessment.

Monitoring of the biological response to murine hindlimb ischemia with 64Cu-labeled vascular endothelial growth factor-121 positron emission tomography.

Imaging of VEGF receptor in a rat myocardial infarction model using PET

Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer.

P304

1-13

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P577

2012-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22229128

http://www.w3.org/2001/XMLSchema#string

P921

P932

3249831

http://www.w3.org/2001/XMLSchema#string